Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Rheumatology (Oxford, England)|November 1, 2024
Temporal and regional variation in the use of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort studyMark D Russell, Zijing Yang, Niamh Dooley, et al.
The Journal of Infection|March 22, 2021
IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regressionEmmanuel Tharmarajah, April Buazon, Vishit Patel, et al.
The Lancet. Rheumatology|October 18, 2024
Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort studyMark D Russell, Mark Gibson, Benjamin Zuckerman, et al.
Annals of the Rheumatic Diseases|July 10, 2026
Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTsMark Gibson, Victoria Allen, Maryam Adas, et al.
Plos One|January 13, 2022
Inpatient COVID-19 mortality has reduced over time: Results from an observational cohortKatie Bechman, Mark Yates, Kirsty Mann, et al.
The Lancet. Rheumatology|November 30, 2022
Incidence and management of inflammatory arthritis in England before and during the COVID-19 pandemic: a population-level cohort study using OpenSAFELYMark D Russell, James B Galloway, Colm D Andrews, et al.
Rheumatology (Oxford, England)|June 5, 2025
Risk of infection in patients with early inflammatory arthritis: results from a large UK prospective observational cohort studyMaryam A Adas, Katie Bechman, Mark D Russell, et al.
The Lancet. Rheumatology|January 22, 2024
Gout incidence and management during the COVID-19 pandemic in England, UK: a nationwide observational study using OpenSAFELYMark D Russell, Jon Massey, Edward Roddy, et al.
The Lancet. Rheumatology|November 15, 2021
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort studySatveer K Mahil, Katie Bechman, Antony Raharja, et al.
The Lancet. Rheumatology|July 14, 2021
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort studySatveer K Mahil, Katie Bechman, Antony Raharja, et al.
Pageof 7